Nothing Special   »   [go: up one dir, main page]

WO2024084400A3 - Alpha 2 macroglobulin, soluble klotho and the use thereof - Google Patents

Alpha 2 macroglobulin, soluble klotho and the use thereof Download PDF

Info

Publication number
WO2024084400A3
WO2024084400A3 PCT/IB2023/060487 IB2023060487W WO2024084400A3 WO 2024084400 A3 WO2024084400 A3 WO 2024084400A3 IB 2023060487 W IB2023060487 W IB 2023060487W WO 2024084400 A3 WO2024084400 A3 WO 2024084400A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
treating
cov
sars
coronavirus
Prior art date
Application number
PCT/IB2023/060487
Other languages
French (fr)
Other versions
WO2024084400A2 (en
Inventor
Syed HAQ
Original Assignee
Bio Immunitas Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Immunitas Ltd. filed Critical Bio Immunitas Ltd.
Publication of WO2024084400A2 publication Critical patent/WO2024084400A2/en
Publication of WO2024084400A3 publication Critical patent/WO2024084400A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure relates generally to alpha 2 macroglobulin (A2M) protein and soluble Klotho (sKL) protein, compositions comprising same, and related uses (e.g., treating a coronavirus (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, treating post-acute sequelae (PASC), treating inflammation, treating bacterial infection, inhibiting an interaction between a SARS-CoV-2 spike protein and an angiotensin-converting enzyme 2 (ACE2) protein, inhibiting a coronavirus (e.g., SARS-CoV-2) papain-like protease (PLpro) protein, rejuvenating skin, and cosmetically treating skin).
PCT/IB2023/060487 2022-10-17 2023-10-17 Alpha 2 macroglobulin, soluble klotho and methods of use thereof WO2024084400A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263416734P 2022-10-17 2022-10-17
US63/416,734 2022-10-17
US202363443830P 2023-02-07 2023-02-07
US63/443,830 2023-02-07
US202363451381P 2023-03-10 2023-03-10
US63/451,381 2023-03-10

Publications (2)

Publication Number Publication Date
WO2024084400A2 WO2024084400A2 (en) 2024-04-25
WO2024084400A3 true WO2024084400A3 (en) 2024-06-06

Family

ID=88585152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/060487 WO2024084400A2 (en) 2022-10-17 2023-10-17 Alpha 2 macroglobulin, soluble klotho and methods of use thereof

Country Status (2)

Country Link
TW (1) TW202421658A (en)
WO (1) WO2024084400A2 (en)

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290762A (en) * 1986-12-24 1994-03-01 John Lezdey Treatment of inflammation
US6294181B1 (en) * 1998-11-05 2001-09-25 Protease Sciences, Inc Cosmetic compositions containing serine protease inhibitors
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
WO2015031654A2 (en) * 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
WO2017085317A1 (en) * 2015-11-19 2017-05-26 Universitat Autonoma De Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments
US20170355749A1 (en) * 2014-11-20 2017-12-14 Cytonics Corporation Therapeutic variant alpha-2-macroglobulin compostions
WO2018211014A1 (en) * 2017-05-18 2018-11-22 Apc Europe Slu Animal plasma or fractions thereof for use in treating cognitive impairment disorders in humans and companion animals
US20180353543A1 (en) * 2015-08-13 2018-12-13 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
CN112195165A (en) * 2020-10-15 2021-01-08 广东药科大学 Anti-aging secretory Klotho protein, and coding gene, recombinant expression vector and application thereof
US20210069305A1 (en) * 2015-02-06 2021-03-11 The Regents Of The University Of California Methods and compositions for improved cognition
US20210388380A1 (en) * 2020-06-10 2021-12-16 Gail Marion Humble Process to produce klotho protein in vitro
WO2022008971A2 (en) * 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
FR3119541A1 (en) * 2021-02-10 2022-08-12 Marc Bonneau Preparation, properties and applications of medicinal compositions containing serum globulins with antiviral activities

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290762A (en) * 1986-12-24 1994-03-01 John Lezdey Treatment of inflammation
US6294181B1 (en) * 1998-11-05 2001-09-25 Protease Sciences, Inc Cosmetic compositions containing serine protease inhibitors
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
WO2015031654A2 (en) * 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
US20170355749A1 (en) * 2014-11-20 2017-12-14 Cytonics Corporation Therapeutic variant alpha-2-macroglobulin compostions
US20210069305A1 (en) * 2015-02-06 2021-03-11 The Regents Of The University Of California Methods and compositions for improved cognition
US20180353543A1 (en) * 2015-08-13 2018-12-13 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
WO2017085317A1 (en) * 2015-11-19 2017-05-26 Universitat Autonoma De Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments
WO2018211014A1 (en) * 2017-05-18 2018-11-22 Apc Europe Slu Animal plasma or fractions thereof for use in treating cognitive impairment disorders in humans and companion animals
US20210388380A1 (en) * 2020-06-10 2021-12-16 Gail Marion Humble Process to produce klotho protein in vitro
WO2022008971A2 (en) * 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
CN112195165A (en) * 2020-10-15 2021-01-08 广东药科大学 Anti-aging secretory Klotho protein, and coding gene, recombinant expression vector and application thereof
FR3119541A1 (en) * 2021-02-10 2022-08-12 Marc Bonneau Preparation, properties and applications of medicinal compositions containing serum globulins with antiviral activities

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN JIANGLEI ET AL: "Secreted Klotho Attenuates Inflammation-Associated Aortic Valve Fibrosis in Senescence-Accelerated Mice P1", HYPERTENSION, vol. 71, no. 5, 1 May 2018 (2018-05-01), US, pages 877 - 885, XP055838421, ISSN: 0194-911X, DOI: 10.1161/HYPERTENSIONAHA.117.10560 *
HAIPENG HUI ET AL: "Klotho suppresses the inflammatory responses and ameliorates cardiac dysfunction in aging endotoxemic mice", ONCOTARGET, vol. 8, no. 9, 28 February 2017 (2017-02-28), pages 15663 - 15676, XP055758477, DOI: 10.18632/oncotarget.14933 *
MASSÓ A ET AL: "Secreted [alpha]Klotho isoform protects against age-dependent memory deficits", MOLECULAR PSYCHIATRY, NATURE PUBLISHING GROUP UK, LONDON, vol. 23, no. 9, 31 October 2017 (2017-10-31), pages 1937 - 1947, XP036858928, ISSN: 1359-4184, [retrieved on 20171031], DOI: 10.1038/MP.2017.211 *
OGUNTUYO KASOPEFOLUWA Y ET AL: "In plain sight: the role of alpha-1-antitrypsin in COVID-19 pathogenesis and therapeutics", BIORXIV, 15 August 2020 (2020-08-15), pages 1 - 27, XP055795146, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.08.14.248880v1.full.pdf> [retrieved on 20210414], DOI: 10.1101/2020.08.14.248880 *
SEITZ RAINER ET AL: "Thromboinflammation in COVID-19: Can [alpha]2-macroglobulin help to control the fire?", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 19, no. 2, 1 February 2021 (2021-02-01), pages 351 - 354, XP093117598, ISSN: 1538-7836, Retrieved from the Internet <URL:https://dul.usage.elsevier.com/doi/> [retrieved on 20240108], DOI: 10.1111/jth.15190 *
VANDOOREN JENNIFER ET AL: "Alpha-2-Macroglobulin in Inflammation, Immunity and Infections", FRONTIERS IN IMMUNOLOGY, vol. 12, 14 December 2021 (2021-12-14), XP055950273, DOI: 10.3389/fimmu.2021.803244 *

Also Published As

Publication number Publication date
WO2024084400A2 (en) 2024-04-25
TW202421658A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
DE60132113D1 (en) STABILIZED COMPOSITION FOR ENZYMATIC REMOVAL OF WOOD GRIND
AU6747501A (en) Combinations of enzyme inhibitor-containing preparations and the use thereof
EP1353684B8 (en) Use of inhibitors of dipeptidypeptidase iv (ec 3.3.14.5) and aminopeptidase n (ec 3.4.11.2) for the treatment of neurodegeneration induced by ischaemia
NZ595193A (en) Modified Proteases That Inhibit Complement Activation
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
AU4923093A (en) Inhibitors of metazoan parasite proteases
BRPI0507971A (en) compound, pharmaceutical composition, use of a compound, method to inhibit the proteolytic activity of a postproline cleavage enzyme and packaged medicine
ATE107660T1 (en) THERAPEUTIC AGENT.
ATE277943T1 (en) TRYPSIN INHIBITORS
AU2002325782A1 (en) Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation
ATE226588T1 (en) PHOSPHIC ACID DERIVATIVES
WO2021236957A3 (en) Ace2 muteins and methods of using the same
Di Pasquale et al. Collagenase‐assisted wound bed preparation: An in vitro comparison between Vibrio alginolyticus and Clostridium histolyticum collagenases on substrate specificity
TR199802638T2 (en) Use of naaladase inhibitors in cancer treatment.
WO2024084400A3 (en) Alpha 2 macroglobulin, soluble klotho and the use thereof
HUP0002644A2 (en) Phartmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor
WO2006096769A3 (en) Use of alpha-glucosidase inhibitors to treat alphavirus infections
WO2001049309A3 (en) Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue
US6280728B1 (en) Treatment of hepatitis C virus infection using a protease and a flavonoid
WO2019055884A3 (en) Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases
Herman et al. Protease technology in wound repair
DE50102739D1 (en) Arzneimittel enthaltend tissue inhibitor of metalloproteinases-2 (timp-2) als osteoanabol wirksame substanz
DE60015559D1 (en) SENTRIN-SPECIFIC HUMAN PROTEASE SENP1
WO2024026308A3 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
WO2002068389A3 (en) Indole derivatives with inhibitor effects on phenol oxidase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23797878

Country of ref document: EP

Kind code of ref document: A2